{"id":989550,"date":"2026-08-04T13:00:27","date_gmt":"2026-08-04T17:00:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/embc-investor-alert-embecta-corp-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\/"},"modified":"2026-08-04T13:00:27","modified_gmt":"2026-08-04T17:00:27","slug":"embc-investor-alert-embecta-corp-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/embc-investor-alert-embecta-corp-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\/","title":{"rendered":"EMBC INVESTOR ALERT: Embecta Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n SAN FRANCISCO<\/span>, Aug. 4, 2026<\/span> \/PRNewswire\/ — Hagens Berman, a leading national shareholder rights law firm, is conducting an investigation into Embecta Corp. (NASDAQ: EMBC<\/b>) regarding alleged<\/span> violations of federal securities laws. This investigation follows the recent filing of a class action lawsuit in the U.S. District Court for the District of New Jersey, which alleges<\/span> that Embecta misrepresented the commercial stability of its insulin pen needle business.<\/p>\n

\n

\n \"Class\n <\/p>\n<\/p><\/div>\n

The firm encourages Embecta investors who suffered substantial losses to submit your losses now<\/a>.<\/p>\n

\n Class Period: <\/b>Nov. 25, 2025 \u2013 May 4, 2026
Lead Plaintiff Deadline: <\/b>Aug. 17, 2026
Visit:<\/b>\u00a0www.hbsslaw.com\/investor-fraud<\/span>\/embc<\/a>
Contact the Firm Now: <\/b>EMBC@hbsslaw.com<\/a>
\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 844-916-0895<\/p>\n

\n Focus of Embecta (EMBC) Securities Class Action:<\/b>\n <\/p>\n

The pending securities class action alleges<\/span> that Embecta and its management misled investors regarding the stability and commercial strength of its core insulin pen needle business. The complaint contends that throughout the class period, Embecta repeatedly assured investors that its pen needle portfolio was “stable,” “resilient,” and “incredibly resolute.” Plaintiffs allege<\/span> these statements were materially false and misleading because, in reality, the company was experiencing significant competitive share loss\u2014particularly at a major customer\u2014and broader market volume softness in the retail channel, all of which management allegedly<\/span> knew or recklessly disregarded while reaffirming its positive financial guidance.<\/p>\n

The truth behind these alleged<\/span> misrepresentations was revealed on May 5, 2026, when in delivering its second-quarter fiscal 2026 financial results Embecta admitted to a massive revenue decline, citing specific headwinds in the U.S. pen needle market that contradicted its prior assurances. The company slashed its full-year 2026 adjusted EPS guidance by approximately 43% at the midpoint and announced a drastic 93% reduction in its quarterly dividend, dropping it from $0.15 to $0.01 per share.<\/p>\n

The market response to this news was immediate and severe, causing Embecta’s stock price to plummet 57.8% over a single trading day.<\/p>\n

“We are investigating whether Embecta’s assurances were misleading, given that the company later reported a significant revenue decline and cited market volume softness,” said Reed Kathrein<\/b><\/a>, the Hagens Berman partner leading the firm’s investigation of the pending claims.<\/p>\n

\n Investor Rights<\/b>\n <\/p>\n

Investors who purchased or acquired Embecta common stock during the Class Period are encouraged to contact our legal team.<\/p>\n